Editorial on “Gene expression signatures in circulating tumor cells correlate with response to therapy in metastatic breast cancer”

Αreti Strati, Vassilis Georgoulias


Breast cancer recurrences, especially in patients with estrogen receptor (ER)-negative disease occur within the first 5 years after diagnosis (1). Several therapeutic options are available for the treatment of metastatic breast cancer, such as surgery, radiotherapy, hormone treatment, chemotherapy as well as targeted therapies (2). However, it would be very important to predict which patients will benefit from each treatment, since several patients experience significant treatment-related adverse events without any clinical benefit.

Download Citation